from the October 2008 issue

Frost & Sullivan cites TransPharma for its innovative ViaDerm drug delivery system

The 2008 Frost & Sullivan European Transdermal Drug Delivery Product Innovation Award is conferred on Israel-based TransPharma Medical Ltd. in recognition of its innovative ViaDerm drug delivery system. The company's two flagship drug product development programs - ViaDerm hPTH (1-34) for the treatment of osteoporosis and ViaDerm-hGH for the treatment of human growth hormone deficiencyare both in phase 2 of clinical development.

The unique ViaDerm system solution allows for low-cost, patient-friendly transdermal delivery of a wide variety of drugs from a patch. Suitable for home use, the ViaDerm system employs a re-usable battery-operated handheld electronic device in combination with a patch containing the drug.

The basis of the ViaDerm device is TransPharma's proprietary RF-MicroChannel technology which is applied to create an array of microscopic pores in the outer skin surface, facilitating the systemic delivery of drugs," explains Frost & Sullivan Research Analyst Sylvia Miriyam Findlay. "The pores are created rapidly with no pain or trauma to the skin. The device can be applied to all skin types and is fully controlled by a unique feedback mechanism that ensures precise and reproducible drug delivery."

TransPharma Medical aims to deliver the best solutions for unmet needs in transdermal drug delivery. It has attempted to meet the challenge of delivering large peptide and proteins by introducing the dry Printed Patch to complement its innovative RF-MicroChannel technology. The printed patch uses the dry form of the drug, thereby increasing stability and shelf life at room temperature.

"TransPharma Medical has constantly worked to spread its novel technology for transdermal drug delivery in therapeutic areas such as endocrine, pain, osteoporosis and diabetes," adds Findlay. "Its application can cover a wide range of therapeutic molecules like hPTH, hGH, GLP-1 analogues, Granisetron, Calcitonine, Testosterone, Diclofenac, and more."

The company has sought to forge productive partnerships with pharmaceutical and biotechnology companies, which will maximize the synergy between its innovative technology and pharmaceutical companies' pipelines. Accordingly, TransPharma Medical has a strategic collaboration with Elli Lilly for the development and commercialization of ViaDerm-hPTH (1-34) for the treatment of osteoporosis. The product, currently in Phase 2 testing, is administered transdermally and thus can enable patients to manage their disease while eliminating the need for daily painful injections.

Reprinted from the Israel High-Tech & Investment Report October 2008

Click HERE to request further information.
Click HERE to go BACK.